![](https://news.europawire.eu/wp-content/uploads/2014/08/Boehringer-Ingelheim.gif)
Initial combinations of empagliflozin and metformin in patients with T2D led to significant reductions in blood glucose vs. empagliflozin or metformin alone at 24 weeks Ingelheim, Germany and Indianapolis, US, 8-6-2015 — /EuropaWire/ — A Phase III clinical trial has … Read the full press release